Jiangsu Yahong Meditech Future Growth
Future criteria checks 2/6
Jiangsu Yahong Meditech is forecast to grow earnings and revenue by 28.3% and 43.3% per annum respectively. EPS is expected to grow by 28.8% per annum. Return on equity is forecast to be -11.3% in 3 years.
Key information
28.3%
Earnings growth rate
28.8%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 43.3% |
| Future return on equity | -11.3% |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 532 | -214 | -448 | -402 | 2 |
| 12/31/2025 | 332 | -291 | -498 | -354 | 2 |
| 12/31/2024 | 185 | -418 | -551 | -520 | 2 |
| 9/30/2024 | 150 | -403 | -452 | -439 | N/A |
| 6/30/2024 | 94 | -399 | -464 | -440 | N/A |
| 3/31/2024 | 38 | -420 | -549 | -450 | N/A |
| 12/31/2023 | 14 | -400 | -500 | -398 | N/A |
| 9/30/2023 | 3 | -352 | -467 | -359 | N/A |
| 6/30/2023 | 0 | -342 | -447 | -347 | N/A |
| 3/31/2023 | 0 | -262 | -278 | -250 | N/A |
| 12/31/2022 | 0 | -247 | -269 | -242 | N/A |
| 9/30/2022 | 0 | -226 | -240 | -229 | N/A |
| 6/30/2022 | 0 | -199 | -208 | -200 | N/A |
| 3/31/2022 | 0 | -196 | -231 | -206 | N/A |
| 12/31/2021 | 0 | -235 | -214 | -172 | N/A |
| 12/31/2020 | N/A | -247 | -140 | -126 | N/A |
| 12/31/2019 | N/A | -172 | -90 | -89 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688176 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688176 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688176 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688176's revenue (43.3% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688176's revenue (43.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688176 is forecast to be unprofitable in 3 years.